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Background: While glucocorticoids and the liganded glucocorticoid receptor (GR) have a well-established role in
the maintenance of differentiation and suppression of apoptosis in breast tissue, the involvement of unliganded GR
in cellular processes is less clear. Our previous studies implicated unliganded GR as a positive regulator of the BRCA1
tumour suppressor gene in the absence of glucocorticoid hormone, which suggested it could play a similar role in
the regulation of other genes.
Methods: An shRNA vector directed against GR was used to create mouse mammary cell lines with depleted
endogenous levels of this receptor in order to further characterize the role of GR in breast cells. An expression
microarray screen for targets of unliganded GR was performed using our GR-depleted cell lines maintained in the
absence of glucocorticoids. Candidate genes positively regulated by unliganded GR were identified, classified by
Gene Ontology and Ingenuity Pathway Analysis, and validated using quantitative real-time reverse transcriptase
PCR. Chromatin immunoprecipitation and dual luciferase expression assays were conducted to further investigate
the mechanism through which unliganded GR regulates these genes.
Results: Expression microarray analysis revealed 260 targets negatively regulated and 343 targets positively regulated
by unliganded GR. A number of the positively regulated targets were involved in pro-apoptotic networks, possibly
opposing the activity of liganded GR targets. Validation and further analysis of five candidates from the microarray
indicated that two of these, Hsd11b1 and Ch25h, were regulated by unliganded GR in a manner similar to Brca1 during
glucocorticoid treatment. Furthermore, GR was shown to interact directly with and upregulate the Ch25h promoter in
the absence, but not the presence, of hydrocortisone (HC), confirming our previously described model of gene regulation
by unliganded GR.
Conclusion: This work presents the first identification of targets of unliganded GR. We propose that the balance between
targets of liganded and unliganded GR signaling is responsible for controlling differentiation and apoptosis, respectively,
and suggest that gene regulation by unliganded GR may represent a mechanism for reducing the risk of breast
tumourigenesis by the elimination of abnormal cells.
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Hormonal signaling plays an integral role in the regulation
of mammary gland function and differentiation. In vivo,
the glucocorticoid hormone cortisol is involved in the
maintenance of breast functional differentiation during
the latter stages of pregnancy, where it induces the forma-
tion of the rough endoplasmic reticulum [1], and regulates
the release of milk proteins [2]. Following weaning, a de-
crease in circulating levels of cortisol is responsible for the
onset of the apoptotic process of involution, where the
mammary tissue morphology is reverted to a quiescent
state [3]. The nature of cortisol’s ability to suppress apop-
tosis in the breast appears to be dependent on the cellular
differentiation state, since glucocorticoids induce cell cycle
inhibitors such as p21 in undifferentiated cells, while they
reduce their expression and inhibit apoptosis in differenti-
ated cells [4]. The intracellular receptor for cortisol, the
glucocorticoid receptor (GR), is ubiquitously expressed in
the human breast, being observed in the nuclei and cyto-
plasm of both luminal epithelial cells and myoepithelial
cells, as well as in the nuclei of stromal cells, endothelial
cells, and adipocytes [5-7]. GR-knockout mice die shortly
after birth due to lung immaturity and respiratory failure,
illustrating that expression of GR is essential for life [8].
Consequently, mutagenesis and Cre-LoxP recombination
targeting of breast epithelial cells in adult mice have been
used to explore the role of GR in mammary gland devel-
opment and function [1,9-11]. GR with a point mutation
in the second zinc finger of the DNA-binding domain
(exon 4; A458T) cannot bind a canonical Glucocorticoid
Response Element (GRE), but retains its ability to transre-
press gene expression through protein-protein interactions
[9]. Virgin mice expressing this DNA-binding GR mutant
exhibit impaired ductal development while lactating mice
exhibit normally differentiated mammary glands capable of
milk production, emphasizing that transcriptional regulation
by protein-protein interactions, rather than DNA-binding,
forms the basis of glucocorticoid action during this process
[1]. In support of this, loss of breast epithelial GR results in
delayed development of the lobuloalveolar compartment
during pregnancy as a result of decreased cell proliferation,
but during lactation, GR-deficient mammary epithelium is
capable of milk production and secretion following in-
creased epithelial proliferation after parturition in the mu-
tant glands [10]. GR contributes to mammary lobular unit
spatial formation through its ability to stimulate the expres-
sion of proteins essential for the spatial organization of the
acini, such as the integrin beta-4 subunit [12]. It is clear that
glucocorticoids and therefore liganded GR are essential for
the growth and differentiation of the mammary gland, as
well as the suppression of apoptosis; however, the role of
unliganded GR in these processes has not been investigated.
Our previous studies indicated that unliganded GR is re-
cruited to and positively regulates the BRCA1 promoterthrough its interaction with the beta subunit of GABP. The
addition of hydrocortisone (HC) abolishes this effect and re-
sults in decreased BRCA1 expression [13]. The positive regu-
latory effect of unliganded GR appeared to be constitutive,
involving basal GR levels within breast cells, since no stimu-
lus or secondary messenger was required for its activation,
unlike other reports of ligand-independent activation by
other steroid hormone receptors which have typically been
in response to other stimuli [14]. Consequently, our model
of BRCA1 activation by unliganded GR is a novel mechan-
ism of GR regulation, and it is possible that the unliganded
receptor may be involved in the regulation of multiple genes
in this manner. Previous efforts to identify targets of GR
regulation have involved expression microarray following
treatment of human breast cells with dexamethasone, thus
revealing genes both positively and negatively regulated by
liganded GR (i.e. glucocorticoid-regulated genes) [15]. ChIP-
chip analysis was used to investigate promoter occupancy by
liganded GR and revealed that GR was bound predominately
near genes responsive to glucocorticoids in A549 lung cells
and not at genes regulated by GR in other cell types exam-
ined [16]. ChIP-seq analysis of GR binding sites in A549 cells
revealed approximately 2600 genes that are weakly bound by
unliganded GR [17], and although the identities of these
genes were not investigated, this study suggested to us that
gene regulation by unliganded GR is not only plausible but it
may be widespread.
In the current study, we used an shRNA directed against
GR to create mouse mammary epithelial cell lines with de-
pleted endogenous GR expression. These cell lines were
used to identify genes up and downregulated in the ab-
sence of endogenous unliganded GR expression using ex-
pression microarray. We found that in cells depleted of
GR, 260 genes were significantly upregulated, while 343
genes were significantly downregulated. Since the down-
regulated genes represented those which are positively reg-
ulated by unliganded GR, potentially through a mechanism
similar to that reported for BRCA1 [13], we examined the
most significant networks comprised of this gene set via
pathway analyses, and determined that several of these
genes were involved in pro-apoptotic networks. Validation
and further analysis of five candidates of positive regulation
by unliganded GR indicated that two of these, Hsd11b1
and Ch25h, were also downregulated following HC treat-
ment, in a manner similar to Brca1. Furthermore, GR was
shown to interact directly with and upregulate the expres-
sion of the Ch25h promoter in the absence, but not the
presence, of HC, confirming our previously described
model of gene regulation by unliganded GR.
Methods
Cell culture and treatments
The non-malignant murine mammary epithelial cell line
EPH-4, which was derived from spontaneously immortalized
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Calvin Roskelley (University of British Columbia, Vancouver,
Canada). EPH-4 cells were cultured as previously described
[13,19]. EPH-4 cells stably transfected with H1-2 empty vec-
tor or shGR (see below) were maintained in serum-free
media with 2 μg/mL puromycin (Sigma). Cell treatments
were completed using media lacking serum and containing
either 1 μg/mL hydrocortisone (HC) (Sigma), 10 μM RU-
486 (Sigma), or ethanol vehicle for 48 hours.
DNA constructs
Creation of the L6-pRL BRCA1 promoter construct, the
H1-2 and shGR vectors, as well as GR FL and GRΔLBD
(originally named GR TAD-DBD-HR) has been described
previously [13,20]. The rat construct GRwt (wild-type GR)
was a gift of Keith Yamamoto (University of California, San
Francisco, USA), and its construction has been described
previously [21]. The pCAGGS-GABPα and pCAGGS-
GABPβ constructs were obtained from Hiroshi Handa
[22]. The Ch25h promoter fragments Ch25h-9, Ch25h-
10, Ch25h-11, Ch25h-11.5, Ch25h-12 were PCR amplified
from EPH-4 genomic DNA using primers listed in
Additional file 1: Table S1. To construct the Ch25h pro-
moter reporter vectors, Ch25h PCR products were cut with
Bam HI/Sal I and ligated into pRL-null (Promega), which
was cut with Bgl II and Sal I. Each Ch25h promoter frag-
ment was cloned into pRL-null upstream of the Renilla lu-
ciferase (R-luc) sequence.
Transient transfections and luciferase assays
Approximately 24 hours prior to transfection, EPH-4, EPH-
4 EV-50, or EPH-4 shGR-19 cells were plated in serum-
containing medium on 12-well culture dishes at a density
of 5 × 104 cells/mL. Cells were transfected in triplicate with
1 μL per well of FuGENE®6 transfection reagent (Roche
Applied Science). Control cytomegalovirus (CMV)-luc vec-
tor (Promega) was used at 25 ng per well, as were expres-
sion vectors and empty vector controls. The remainder of
the 250 ng per well was allotted to the appropriate Renilla
luciferase reporter vector. Cells were treated with HC or
ethanol vehicle (as described above) in serum-free medium
24 hours following transfection. Forty-eight hours after
treatment, cells were harvested for the Dual-Luciferase® Re-
porter Assay (Promega) as previously described [13,23].
Creation of EPH-4 shGR stable cells
Approximately 24 hours prior to transfection, EPH-4 cells
were plated in serum-containing medium on 100 mm cul-
ture dishes at a density of 5 × 104 cells/mL. Cells were
transfected with 11.25 μL per plate of FuGENE®6 transfec-
tion reagent along with 380 ng of pBABE-puro selectable
marker and 3420 ng of either H1-2 empty vector or shGR
(1:10 ratio). Following a 24 hour incubation, cells were
lifted, diluted 1:20 and re-plated, and subsequently putinto 2 μg/mL puromycin selection following another
24 hours. Colonies were lifted using filter paper, expanded,
and cell lysates were screened by Western blot for GR
protein levels using TBP as a loading control. The result-
ant stable cell lines EV-50, shGR-73, and shGR-19 were
maintained with 2 μg/mL puromycin in media without
serum.
Western blot
Lysates were prepared in 1X SDS loading buffer and an-
alyzed by standard Western blotting procedures. Polyvi-
nylidene fluoride membranes (Millipore) were probed
with the appropriate primary antibody: anti-GR (1:500;
ab3579; Abcam), or anti-TBP (1:2,000; ab818; Abcam).
The secondary antibodies used included goat anti-rabbit
(1:10,000; sc-2004; Santa Cruz Biotechnology Inc.) and
goat anti-mouse (1:10,000; 115-035-003; Jackson Immu-
noResearch). Secondary antibody detection was per-
formed by chemiluminescence (SuperSignal® West Pico,
Thermo Scientific/Fisher).
Quantitative real-time reverse transcription PCR
RNA and RT products were prepared as described
previously [13,19,23]. Quantitative real-time reverse tran-
scription PCR (qRT-PCR) reactions were performed
using TaqMan® gene expression assays (Life Tech-
nologies) for mouse Nr3c1 (GR) (Mm00433832_m1)
Brca1 (Mm01249840_m1), Oas2 (Mm00460961_m1),
Ces1 (Mm00491334_m1), Hsd11b1 (Mm00476182), Ch25h
(Mm00515486_s1), Slc5a9 (Mm00523837_m1). Mouse Tbp
was used as an internal control for all qRT-PCR experi-
ments (Mm00446971_m1; Life Technologies). Quantitative
RT-PCR reactions were performed using the SuperScript®
III Platinum® One-Step Quantitative RT-PCR system (Invi-
trogen) with 50–250 ng RNA in triplicate and 1 μL Taq-
Man® gene expression assay per reaction. The PCR
protocol consisted of one cycle of (900 sec at 50°C and
120 sec at 95°C), followed by 40 cycles of (15 sec at 95°C
and 30 sec at 60°C), and was run on an Eppendorf Master-
cycler®. Gene expression was calculated relative to the re-
sults for the untreated or empty vector sample with the
comparative Ct (ΔΔCt) method presented by PE Applied
Biosystems (Perkin Elmer).
ChIP assay
EPH-4 cells were plated and treated as described above.
ChIP assays were performed with the ChIP-IT™ Ex-
press Enzymatic kit (Active Motif, Carlsbad, CA, USA).
Each reaction was performed using chromatin from 2 ×
106 cells and 2 μg per reaction of affinity-purified an-
tibody (or water as a no antibody negative control).
The following antibodies were used: anti-GR (ab3579;
Abcam), anti-GABPα (sc-22810; Santa-Cruz), anti-GABPβ
(sc-28684; Santa Cruz) anti-haemaglutinin (sc-805; Santa-
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Biotechnology, Lake Placid, NY, USA). Walking PCR
primers were designed to cover approximately 3000 bp of
each the Ch25h, Hsd11b1 distal P1, and Hsd11b1 proximal
P2 promoter regions (primers listed in Additional file 1:
Tables S2-S4). The PCR protocol consisted of one cycle of
180 sec at 95°C followed by 38 cycles of (30 sec at 95°C,
30 sec at 60°C, 30 sec at 72°C) and a final cycle of 240 sec
at 72°C. ChIP DNA was quantified by quantitative PCR
using the QuantiTect SYBR Green PCR kit using 2 μL of
ChIP DNA and ChIP PCR primers for mouse Ch25h “re-
gion 11” from position −447 to −118 ((+) 5’-CAACG
GACCCAGTACCAGCA and (−) 5’-ACGTAAAGAACT
GTTTGCTTGCC. The PCR protocol consisted of one
cycle of 900 sec at 94°C followed by 40 cycles of (30 sec at
94°C, 30 sec at 60°C, 30 sec at 72°C).
Expression microarray
RNA was prepared as described previously [13,19,23]
from EPH-4 EV-50 and shGR-19 stable cell lines. The
quality of total RNA was determined with an Agilent
2100 Bioanalyzer (Agilent Technologies). The samples
were selected for microarray analysis or for qRT-PCR
provided that they had an RNA integrity number (RIN)
>7.0, a clear gel image, and no DNA contamination ob-
served on the histogram. A total of 300 ng quality-
checked total RNA from each sample (in duplicate) was
amplified and labeled with Cy3 using the Agilent Quick-
Amp kit (Agilent Technologies). Cy3 labeling efficiency
and amplification efficiency were assessed using a Nano-
Drop ND-1000 spectrophotometer (NanoDrop Tech-
nologies). 1.65 μg of Cy3-labeled cRNA for each sample
was hybridized to an Agilent Whole Mouse Genome 4 ×
44 K gene expression array (G2519F-014868, Agilent
Technologies). After 17 hours of hybridization, arrays
were washed and scanned according to the Agilent gene
expression array protocol. The data was normalized by
the Feature Extraction software (10.5.1.1) with default
parameter settings for one-colour oligonucleotide micro-
arrays and then transferred to GeneSpring GX version
9.0.2 (Agilent Technologies) for further statistical evalua-
tion. In GeneSpring, normalization and data transformation
steps for one-colour data were applied as recommended
by Agilent Technologies. The data were analyzed using
GeneSpring, and genes with >2.0 fold differential expression
(both increased and decreased; p < 0.01) between EV-50 and
shGR-19 were ranked by fold.
Functional analysis of differentially expressed genes from
microarray data was performed using the Gene Ontology
Enrichment Analysis Software Toolkit (GOEAST) program,
which adjusts the raw p-values into a false discovery rate
using the Benjamini-Yekutieli method [24]. In addition to
classifying genes based on biological process, molecular
function, and cellular component ontologies, we employedIngenuity Pathway Analysis (IPA; http://www.ingenuity.
com) to identify biological networks regulated by GR. The
upregulated and downregulated gene sets between EPH-4
EV-50 and shGR-19, as well as both differentially expressed
sets together, were used for network analysis. Following
GeneSpring analysis, Agilent probe set IDs were uploaded
into IPA and queried with all other genes stored in the In-
genuity Knowledge Base. In reporting our results, we fo-
cused on networks with high IPA network scores, which
demonstrate strong evidence for a given biological pathway
being regulated by GR. The results of our GeneSpring dif-
ferential analysis, as well as the GOEAST and IPA func-
tional analyses, were coalesced in order to construct a list
of candidate genes that may be regulated similarly to Brca1.
Five candidate genes exhibiting decreased differential ex-
pression between EV-50 and shGR-19 were chosen for val-
idation and subsequent analyses.
Statistical analysis
The level of GR knockdown in the EPH-4 stable
cell lines shGR-73 and shGR-19 (relative to EV-50) was
quantified by densitometric analysis of the GR and TBP
Western blots using ImageJ. Standard deviation between
triplicates from qRT-PCR experiments were calculated
according to the ΔΔCt method presented by Applied
Biosystems. Standard deviation between triplicates in lu-
ciferase assays was calculated using Microsoft Excel
2010. Statistical significance calculations for qRT-PCR
experiments and luciferase assays were performed with
GraphPad Prism 5 Software, using the unpaired, two-
tailed t-test function assuming equal variances of the av-
eraged data.
Results
GR and Brca1 levels are decreased in cells stably
expressing shGR
We have previously shown that unliganded GR positively
regulates BRCA1 promoter activity in EPH-4 mouse mam-
mary cells [13]. This effect may be representative of a novel
role for unliganded GR as a transcriptional activator of mul-
tiple genes in the breast. In order to address this hypothesis
as well as study the involvement of unliganded GR in cel-
lular processes, we stably transfected the non-malignant
mouse mammary cell line EPH-4 with a short hairpin RNA
(shRNA) vector directed against human/mouse GR (shGR)
as well as empty H1-2 vector as a control (EV). Protein ly-
sates and RNA were prepared from puromycin-selected
clonal isolates maintained in the absence of glucocorticoids,
and GR expression was examined by Western blot and
qRT-PCR. The stable cell lines shGR-73 and shGR-19 exhib-
ited reduced levels of GR protein (Figure 1A) and expression
of Nr3c1 (GR) mRNA (Figure 1B) relative to the empty vec-
tor control cell line EV-50, with shGR-19 exhibiting the










































































































Figure 1 Expression of GR and Brca1 is decreased in cells stably expressing an shRNA vector against endogenous GR. EPH-4 cells were
stably transfected with a puromycin selectable marker and either an empty vector (H1-2; EV) or an shRNA vector directed against the endogenous
glucocorticoid receptor (shGR). Cells were puromycin-selected and expanded. A. EV-50, shGR-19, and shGR-73 stable clone lines were lysed and
subjected to Western blotting to determine GR expression (shown in left panel). Densitometric analysis was performed to quantify the level of GR
protein knockdown in shGR-73 and shGR-19 relative to EV-50 (shown in right panel; numbers indicate protein levels relative to EV-50). B-C. RNA
was prepared from EPH-4 stable cell lines EV-50, shGR-73, and shGR-19, and qRT-PCR analysis of mouse B. Nr3c1 (GR) and C. Brca1 expression was
conducted using TaqMan gene expression assays for each gene. Raw Ct values for each gene were normalized to raw Ct values for mouse Tbp internal
control for triplicate samples, and are presented as the level of expression relative to the EV-50 sample. Bars represent the mean of technical replicates,
and error bars represent standard deviation (N = 3). Statistically significant changes in gene expression relative to EV-50 are indicated for each gene:
one asterisk, p < 0.05 (significant); two asterisks, p < 0.005 (very significant).
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reduced endogenous Brca1 expression compared with EV-
50 (Figure 1C), which reflects the positive regulatory effect
that GR normally has on this gene. Furthermore, transiently
transfecting the BRCA1 proximal promoter construct L6 re-
sulted in a reduction in its activity by approximately 50% in
shGR-19 cells compared to EV-50 cells in the absence of
HC, indicating that the level of endogenous GR in these
cells is insufficient to positively regulate BRCA1 expression
(Figure 2). In support of this, treatment of shGR-19 cells
with HC did not result in any additional repression of
BRCA1 activity.
Expression microarray analysis
The creation of the stable cell lines EV-50 and shGR-19
afforded us the ability to identify targets exclusively reg-
ulated by unliganded GR by comparing gene expression
in cells depleted of GR (shGR-19) to that in cells ex-
pressing normal endogenous levels of this transcription
factor (EV-50). Whole genome expression microarray
analysis resulted in the identification of a total of 603 en-
tities (genes or transcripts) with at least a 2-fold changeand p < 0.01 between EPH-4 EV-50 and shGR-19 cells,
including 260 upregulated genes and 343 downregulated
genes in shGR-19 relative to EV-50 (see Additional
file 2). The data discussed in this publication have been
deposited in NCBI’s Gene Expression Omnibus [25] and
are accessible through GEO Series accession number
GSE51408 (http://www.ncbi.nlm.nih.gov/geo/query/acc.
cgi?acc=GSE51408). Genes upregulated in shGR-19 com-
pared to EV-50 are likely negatively regulated by unli-
ganded GR, since they are increased in the absence of
endogenous unliganded GR. In contrast, genes downreg-
ulated in shGR-19 compared to EV-50 are positively reg-
ulated by unliganded GR, since they are decreased in the
absence of endogenous unliganded GR. Among the
genes downregulated in shGR-19, the GR gene, Nr3c1,
was decreased approximately 4-fold, confirming the sta-
bility of GR knockdown in this cell line. While Brca1 did
not qualify for the analysis following the 2-fold cutoff, its
expression was decreased approximately 1.5-fold in
shGR-19, confirming our previous report that GR posi-
tively regulates Brca1 activity, since GR depletion results

































Figure 2 BRCA1 promoter activity is reduced and no longer
repressed in the presence of HC in cells stably expressing
shGR. EPH-4 EV-50 and shGR-19 stable cells were transiently transfected
with the L6 BRCA1 promoter reporter construct, treated 24 hours after
transfection with either ethanol vehicle (−HC) or 1 μg/mL HC (+HC),
and assayed for luciferase activity following a 48 hour incubation. Bars
represent the mean of technical replicates, and error bars represent
standard deviation (N = 3). Statistically significant changes in BRCA1
promoter activity relative to EV-50 (−HC) are indicated: one asterisk,
p < 0.05 (significant); two asterisks, p < 0.005 (very significant).
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In order to analyze potential functional trends in our
microarray data, we performed functional analyses of the
lists of differentially expressed up and downregulated
genes. Our Gene Ontology (GO) analysis was completed
using GOEAST (Gene Ontology Enrichment Analysis
Software Toolkit) [24]. This program enabled the deter-
mination of the most highly represented GO categories
in response to GR depletion, and the number of genes in
each set (up and downregulated) belonging to those cat-
egories. This analysis determined that the gene targets
negatively regulated by unliganded GR were involved in
various developmental processes, while the targets of posi-
tive regulation by unliganded GR were involved in pro-
cesses related to immune system regulation and signaling
(see Additional file 3: Figures S1 and S2). Furthermore,
there was little to no overlap in GO terms between the
two gene lists; while several genes positively regulated by
unliganded GR were involved in pro-apoptotic pathways,
a number of genes negatively regulated by unliganded GR
appeared to be anti-apoptotic. In order to examine the
structure of regulatory networks underlying the response
to depleted endogenous GR expression, we performed In-
genuity Pathway Analysis using both sets of differentially
expressed genes between EPH-4 EV-50 and shGR-19, as
well as both differentially regulated gene sets together. Un-
like GO analysis, which classifies individual gene candi-
dates based on function, IPA networks represent generelationships and interactions that are linked to specific
molecular and cellular mechanisms.
IPA revealed that there was a high probability for finding
genes that were negatively regulated by unliganded GR in
a network hub centered on prostaglandin-endoperoxide
synthase 2 (PTGS2; cyclooxygenase (COX)-2) and chemo-
kine signaling (Figure 3). Genes in this “top” network had
p-values of <0.05 based on Fisher’s exact test, and were as-
sociated with cardiovascular system development and
function, cellular movement, and organismal develop-
ment, indicating that unliganded GR, either directly or in-
directly, negatively regulates these processes. This network
was composed primarily of gene candidates of negative
regulation by unliganded GR identified by our microarray
study, as indicated by the shaded entities, while the white
entities represent factors imputed from the IPA Know-
ledge Base (IPA network score = 41).
According to IPA, the genes positively regulated by
unliganded GR from our microarray study had a high
probability of being found in a “top” network signaling
hub involving interferon and immune system signaling.
Genes in this network, with p-values of <0.05, were asso-
ciated with dermatological diseases and conditions, in-
flammatory disease, and neurological disease (Figure 4).
This network was comprised almost entirely of gene
candidates of positive regulation by unliganded GR iden-
tified by the present study (IPA significance score = 41).
The GR gene (Nr3c1), which was downregulated ap-
proximately 4-fold in shGR-19, was central in this path-
way, establishing its direct involvement in the positive
regulation of these processes. Also prominently featured
in this network were Cyclin D2 (CCND2), and members
of the oligoadenylate synthetase (Oas), interferon regula-
tory factor (Irf ), and interferon-induced tetratricopeptide
repeat (Ifit) families of genes. When all entities (ie. both
lists of candidates of negative and positive regulation by
unliganded GR) were analyzed together, there was a high
probability for finding candidate genes from the present
study in a network hub involving interferon and immune
signaling (data not shown). Notably, this pathway con-
sisted primarily of genes from the top network involving
candidates that were downregulated in shGR-19 relative
to EV-50, including Nr3c1 itself, suggesting that these
biological signaling pathways predominantly involve fac-
tors that are positively regulated by unliganded GR. We
hypothesized that these factors may be positively regu-
lated by unliganded GR through the same mechanism as
we have previously identified for Brca1. As such, we fo-
cused primarily on this set of genes, and selected five
candidates for validation and further analysis.
Candidate gene selection
Five candidate genes were selected for microarray valid-
ation and further characterization based on the combined
Figure 3 Ingenuity Pathway Analysis of genes negatively regulated by unliganded GR. IPA identified this hub as the top signaling network
among candidate genes upregulated in EPH-4 shGR-19 compared to EV-50 (IPA network score = 41) i.e. negatively regulated by unliganded GR.
This network was associated with cardiovascular system development and function, cellular movement, and organismal development. Solid lines
indicate a physical interaction between molecules. A solid line with an arrow indicates that one factor acts on the other, while a solid line with a
perpendicular bar at the end denotes that one factor inhibits the other. Dotted lines indicate an indirect cellular interaction between factors.
Shaded molecules represent candidate genes revealed to be upregulated between EPH-4 EV-50 and shGR-19 in our microarray analysis, while
white molecules represent factors imputed from the Ingenuity Knowledge Base. The different shapes of the molecules represent their different
functional activities: square, cytokine; circle, other; triangle, kinase/phosphatase; rectangle, G protein coupled receptor; oval, transcription regulator;
diamond, enzyme. A full explanation of IPA annotation can be found at http://www.springerimages.com/Images/LifeSciences/1-10.1007_s12014-010-9053-0-2.
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GOEAST (see Additional file 3) and IPA functional ana-
lyses, and included Hsd11b1, Ch25h, Ces1, Oas2, and
Slc5a9. Each of these genes was among the top 50 candi-
dates that exhibited at least 10-fold downregulated expres-
sion in shGR-19 compared to EV-50. The Hsd11b1 gene
encodes the enzyme 11β-hydroxysteroid dehydrogenase
type 1, which is responsible for the interconversion of glu-
cocorticoids between inactive cortisone and active cortisol
in humans and between inactive 11-dehydrocorticosterone
and active corticosterone in rodents [26]. Ch25h encodes
the enzyme cholesterol 25-hydroxylase, which catalyzes the
synthesis of 25-hydroxycholesterol from cholesterol and
molecular oxygen [27], and has a role in the regulation of
the innate immune system, where its expression is inducedin the presence of TLR ligands [28,29]. The enzyme carbox-
ylesterase 1 is encoded by the Ces1 gene, which is a serine
esterase that hydrolyzes aromatic and aliphatic esters and
thus maintains the level of free lipids within cells by moni-
toring cholesterol esterification levels [30]. The Oas2 gene
encodes 2′,5’-oligoadenylate synthetase 2, which is a mem-
ber of a family of essential proteins involved in the innate
immune response to viral infection [31]. Oas2 is induced by
interferons to synthesize 2′,5’-oligoadenylates, which acti-
vate latent RNase L, resulting in viral RNA degradation and
the inhibition of viral replication [32]. Oas2 was one mem-
ber of several Oas genes that appeared to be positively
regulated by unliganded GR (Oas1a, Oas1c, Oas3, Oasl1,
Oasl2). The protein encoded by Slc5a9 is a sodium-
dependent glucose transporter that is essential for the
Figure 4 Ingenuity Pathway Analysis of genes positively regulated by unliganded GR. IPA identified this hub as a top signaling network
among candidate genes downregulated in EPH-4 shGR-19 compared to EV-50 (IPA network score = 41) i.e. positively regulated by GR. This network
was associated with dermatological diseases and conditions, inflammatory disease, and neurological disease. Annotation of IPA network shapes and
molecular relationships as specified in Figure 3.
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http://www.biomedcentral.com/1471-2407/14/275transport of mannose, 1,5-anhydro-D-glucitol, and fructose
[33]. Slc5a9 was representative of a larger group of solute
carrier genes that appeared in our gene set comprised of
targets of unliganded GR positive regulation (Slc23a3,
Slc39a4, Slc46a1, Slc7a4).
Candidate gene validation
To validate the microarray, quantitative real-time reverse
transcription PCR (qRT-PCR) was performed to assess
the mRNA expression of the five selected genes that ex-
hibited decreased differential expression between EPH-4
EV-50 and shGR-19 cells, Hsd11b1, Ch25h, Ces1, Oas2,
and Slc5a9, as well as Brca1 and Nr3c1 (Figure 5A-G).
Microarray and qRT-PCR resulted in similar levels (ie.
relative expression in shGR-19 compared to EV-50) of
downregulation for all of these genes, confirming thereliability of our microarray results at the mRNA level
(Table 1). It is of note that while Hsd11b1, Ch25h, and
Slc5a9 were expressed at relatively high levels (ie. raw Ct
values were lower than those of the housekeeping gene,
Tbp), both Ces1 and Oas2 were expressed less abun-
dantly (ie. raw Ct values were higher than those of Tbp,
and in the case of Ces1, values approached the max-
imum number of PCR cycles).
Expression of candidate genes in response to
hydrocortisone and RU-486 treatment
To investigate whether ligand binding to GR exerts the
same effect on our candidate genes as we have previ-
ously reported for BRCA1, we investigated the expres-
sion of each gene in the presence of HC. EPH-4 cells
were treated with HC, and RNA was prepared at 0, 24,





































































































































































Figure 5 Validation of microarray candidate genes. qRT-PCR validation of microarray candidate gene expression was conducted using RNA
prepared from EPH-4 EV-50 and shGR-19 stable cells and TaqMan mouse gene expression assays for each gene: A. Hsd11b1, B. Ch25h, C. Ces1, D.
Oas2, E. Slc5a9, F. Brca1, and G. Nr3c1. Raw Ct values for each gene were normalized to raw Ct values for mouse Tbp internal control for triplicate
samples, and are presented as the level of expression relative to the EV-50 sample. Bars represent the mean of technical replicates, and error bars
represent standard deviation (N = 3). Statistically significant changes in gene expression relative to EV-50 are indicated for each gene: one asterisk,
p < 0.05 (significant); two asterisks, p < 0.005 (very significant); three asterisks, p < 0.0005 (very highly significant).
Table 1 Relative expression of candidate genes in EPH-4
shGR-19 RNA compared to EV-50 RNA in expression
microarray vs. qRT-PCR experiments
Relative expression: shGR-19 vs. EV-50








The fold change output for each gene between shGR-19 and EV-50 from the
microarray data was converted to relative expression by taking the base-2
logarithm of the absolute fold change and setting this value as the negative
exponent of 2. The relative expression values for each gene between shGR-19
and EV-50 in the qRT-PCR were obtained directly during the experimental
analysis (ΔΔCt method).
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http://www.biomedcentral.com/1471-2407/14/275and 48 hours for qRT-PCR analysis. As expected, treat-
ment with HC downregulated Brca1 by about 50% at
both 24 and 48 hours (Figure 6A). Expression of
Hsd11b1 was reduced by about 60% after 24 hours of
HC treatment, and by 40% at 48 hours (Figure 6B). Not-
ably, Hsd11b1 expression increased nearly 3-fold be-
tween 0 and 48 hours in untreated (−HC) cells. HC
treatment resulted in a decrease in Ch25h expression by
approximately 80% after 24 and 48 hours (Figure 6C).
Ces1 expression was also downregulated by HC at both
24 and 48 hours, but large standard deviations indicate
that this gene may not be expressed at adequate levels
(Figure 6D). Expression of Oas2 increased with HC
treatment, by 6- and 8-fold at 24 and 48 hours, respect-
ively (Figure 6E). Slc5a9 was also positively affected by
HC treatment, with expression of this gene increasing 4-
fold after 24 hours and 13-fold after 48 hours (Figure 6F).
Expression of Slc5a9 also increased in untreated cells,
but this effect was less dramatic than in HC-treated






























































































































































































Figure 6 Expression of microarray candidate genes in response to HC treatment. EPH-4 cells were treated 24 hours after plating (ie. at
0 hrs) with either ethanol vehicle (−HC) or 1 μg/mL HC (+HC) in serum-free media for a period of 48 hours. RNA was prepared at 0, 24, and
48 hours, and qRT-PCR analysis of microarray candidate gene expression was conducted using TaqMan mouse gene expression assays for each
gene: A. Brca1 B. Hsd11b1, C. Ch25h, D. Ces1, E. Oas2, F. Slc5a9, and G. Nr3c1. Raw Ct values for each gene were normalized to raw Ct values for
mouse Tbp internal control for triplicate samples, and are presented as the level of expression relative to the -HC sample at 0 hrs. Bars represent
the mean of technical replicates, and error bars represent standard deviation (N = 3). Statistically significant changes in gene expression relative to
the -HC sample for each time point are indicated for each gene: one asterisk, p < 0.05 (significant); two asterisks, p < 0.005 (very significant); three
asterisks, p < 0.0005 (very highly significant).
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http://www.biomedcentral.com/1471-2407/14/275on Oas2 and Slc5a9 expression rather than a repressing
effect, it is possible that these genes are not regulated by
unliganded GR through precisely the same mechanism
as Brca1. Instead, it is possible that unliganded GR may
be poised on a GRE within these promoters but may not
activate transcription until ligand binding, making thesegenes HC-responsive. Expression of Nr3c1 was unaltered
by HC treatment (Figure 6G), indicating GR does not
regulate itself in this context.
We further evaluated the effect of ligand binding on
the expression of both Hsd11b1 and Ch25h with the use
of the GR antagonist, mifepristone (RU-486). RU-486 is
Ritter and Mueller BMC Cancer 2014, 14:275 Page 11 of 19
http://www.biomedcentral.com/1471-2407/14/275a hydrocortisone analogue that is able to bind to GR but
inhibits the transcription of GR target genes [34]. We
have previously demonstrated that treatment of mouse
mammary cells with RU-486 results in decreased expres-
sion of endogenous Brca1, indicating that ligand bind-
ing, even of a nonsignaling ligand, to GR is the key
physiological stimulus for decreased Brca1 expression,
and we suggested that in addition to blocking normal
signaling of liganded GR, the repressive ability of RU-
486 may be partly due to its ability to disrupt unliganded
GR binding at the promoters of its target genes [13]. In
the present study, treatment of EPH-4 cells with RU-486
resulted in decreased expression of both Brca1 and
Ch25h, but not Hsd11b1, which was activated (Figure 7),
suggesting that the regulation of these genes may involve
different mechanisms of GR signaling.
The unliganded glucocorticoid receptor interacts directly
with the Ch25h promoter and upregulates Ch25h activity
Our microarray and further validation experiments indi-
cated that Hsd11b1 and Ch25h were positively regulated
by unliganded GR in the absence of HC and that their
expression decreased upon HC addition. In order to de-
termine whether unliganded GR physically interacts with
the promoters of these genes, we performed ChIP assays
using untreated and HC-treated EPH-4 chromatin and






























Figure 7 Expression of microarray candidate genes in response
to RU-486 treatment. EPH-4 cells were treated 24 hours after plating
(ie. at 0 hrs) with either ethanol vehicle (UT) or 10 μM RU-486 (+RU-486)
in serum-free media for a period of 48 hours, after which RNA was
prepared. qRT-PCR analysis of gene expression was conducted using
TaqMan mouse gene expression assays for Brca1, Hsd11b1, and Ch25h.
Raw Ct values for each gene were normalized to raw Ct values for mouse
Tbp internal control for triplicate samples, and are presented as the level
of expression relative to the UT sample. Bars represent the mean of
technical replicates, and error bars represent standard deviation (N = 3).using walking sets of ChIP primers that covered approxi-
mately 2800 bp upstream and 500 bp downstream of the
defined transcription start sites in both genes (Ch25h
promoter depicted in Figure 8A). These experiments re-
vealed that GR bound specifically to “region 11” between
−447 and −219 bp of Ch25h in the absence of HC, and
that this interaction was abolished in the presence of
HC (Figure 8B). Furthermore, ChIP of the ets family
members GABPα and GABPβ demonstrated that both of
these proteins interacted with this same region of Ch25h
in the absence but not the presence of HC. This result is
of interest since the mechanism by which unliganded
GR upregulates BRCA1 expression involves a protein-
protein interaction with GABPβ at the BRCA1 promoter.
The ChIP DNA samples were analyzed via quantitative
PCR using the ChIP primers for Ch25h “region 11” and
values obtained reflect the pattern of band intensities on
the ChIP gel (Table 2). Neither GR nor GABP bound to ei-
ther the Hsd11b1 P1 (distal) or P2 (proximal) promoters
in the absence or presence of HC (data not shown).
We previously reported that transfection of a GR ex-
pression vector increased BRCA1 activity in transient
transfection assays with the proximal BRCA1 promoter re-
porter. In order to investigate the effect of GR on Ch25h
promoter expression, we transfected EPH-4 cells with
Ch25h reporter constructs of varying lengths: Ch25h-9
(−937), Ch25h-10 (−687), Ch25h-11 (−477), and Ch25h-
11.5 (−375), which each contained Ch25h “region 11”, ei-
ther in its entirety or the proximal half, and Ch25h-12
(−225), which did not contain this region (Figure 9A). This
transfection was performed in the absence (Figure 9B) and
presence of HC (Figure 9C). In the absence of HC, lucifer-
ase activity significantly increased for all reporters contain-
ing this site following the addition of exogenous GR
(GRwt), while it did not increase for Ch25h-12 (Figure 9B).
The level of increase in activity of Ch25h-9, Ch25h-10,
Ch25h-11, and Ch25h-11.5 in response to exogenous GR
addition was comparable to that of BRCA1 (L6) (approxi-
mately 50% increase in relative promoter activity in re-
sponse to GR addition). Treatment with HC resulted in
downregulation of BRCA1 L6 and all Ch25h promoter re-
porters containing the region between −375 and −225 bp
compared to the activity of each observed in the -HC ex-
periment, during transfection with both EV and GRwt
(Figure 9C). Conversely, HC addition had no effect on the
activity of Ch25h-12 compared to the -HC experiment, in-
dicating that this region is not HC-responsive. The effect
of exogenous GR addition on the activity of Ch25h was
also investigated using the EPH-4 clone cell lines EV-50
and shGR-19 in both the absence and presence of HC.
Consistent with the wild-type EPH-4 transfection, activity
of the L6 BRCA1 promoter and all Ch25h reporters con-
taining the region between −375 and −225 bp significantly
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B
Figure 8 GR physically interacts with the Ch25h promoter in the absence of ligand. A. Schematic of walking ChIP primers covering ~2800 bp
upstream and ~500 bp downstream of the transcription start site of Ch25h. The thick black line indicates the Ch25h promoter. The arrow and +1 indicate
the location of the transcription start site. The numbers above indicate the bp location on Ch25h. The boxes below indicate the locations of the ChIP
primers, and the region amplified by each primer set is indicated by a line between the boxes. The numbers above and below these lines indicate the
designated “region” of the Ch25h promoter covered by each primer set. B. Chromatin was prepared from EPH-4 non-malignant mouse mammary cells 24 hours
after treatment with either ethanol vehicle (−HC) or 1 μg/mL HC (+HC) in serum-free medium. ChIP analysis was carried out with the indicated antibodies and
PCR primers amplifying the region between −447 to −219 bp of the Ch25h promoter. Ab, antibody; HA, hemagglutinin; H3, acetylated histone H3.
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lines, while activity of Ch25h-12 was unaltered by GR
addition (Figures 10A and C). The presence of HC had a
repressive effect during EV and GRwt transfections with
L6 BRCA1 and some of the Ch25h reporters in EV-50, but
not shGR-19 cells, emphasizing the difference in endogen-
ous GR levels between these cell lines (Figures 10B and
D). Unlike in the wild-type EPH-4 transfection, the activity
of Ch25h-12 was slightly upregulated in response to HC
during transfection with both EV and GRwt in both
EPH-4 clone cell lines (Figures 10B and D). While
normalization in this experiment was performed separ-
ately within cell lines, it is of note that the Ch25h reporters
were approximately 50% less active in shGR-19 cells than
in EV-50 cells in the -HC experiment (ie. if the cell lines
were compared directly to one another). Collectively, these
assays support the existence of a response element for





No Ab >40 >40
ChIP HA >40 >40
DNA H3 27.94 28.13
Sample GABPα 32.67 >40
GABPβ 33.5 >40
GR 32.5 >40
The ChIP DNA products were analyzed via quantitative PCR using the ChIP
primers for Ch25h “region 11” and expressed as relative Ct values.and that the minimal region required is between −375
and −225 bp.
In order to demonstrate that unliganded GR is respon-
sible for the observed activation of Ch25h, we transiently
transfected EPH-4 cells with the Ch25h promoter re-
porters Ch25h-11.5-pRL (which contains the predicted
minimal GR binding region between −375 and −225 bp)
and Ch25h-12-pRL (does not contain the GR binding re-
gion) along with full length GR (GR FL) and a GR mutant
lacking the entire ligand binding domain (GRΔLBD), each
in the absence and presence of HC treatment. Both GR FL
and GRΔLBD activated Ch25h-11.5-pRL in the absence of
ligand (Figure 11A). While activation by GR FL was abol-
ished upon the addition of HC, activation by GRΔLBD
was sustained in the presence of HC, emphasizing that in
contrast to the wild-type protein, it is now immune to the
effects of HC. This mutant is unable to bind ligand, but
can still maintain its interaction with the Ch25h promoter
and activate its expression. Similar results were obtained
with the Ch25h promoter reporters Ch25h-9-pRL, Ch25h-
10-pRL, and Ch25h-11-pRL (see Additional file 4: Figure
S3). Neither GR FL nor GRΔLBD was able to activate the
construct lacking the GR responsive region (Ch25h-12-
pRL), and its activity was not significantly altered upon
HC addition (Figure 11B), adding further support for the
existence of a response element for unliganded GR con-
tained within the −375 to −225 bp region of Ch25h. The
presence of GABP alone or in combination with the GR
expression vectors did not have a significant effect on the
activity of either Ch25h-11.5-pRL or Ch25h-12-pRL.
These experiments corroborate our previously described
model of gene regulation by unliganded GR in which GR






































































































































Figure 9 GR activates the Ch25h promoter region between −375 and −225 bp only in the absence of HC. A. Schematic of Ch25h
promoter fragments cloned into the pRL-Null vector upstream of the Renilla luciferase (R-luc) gene. B-C. EPH-4 cells were transiently transfected
with the Ch25h promoter reporters Ch25h-9-pRL, Ch25h-10-pRL, Ch25h-11-pRL Ch25h-11.5-pRL Ch25h-12-pRL, and the L6-pRL BRCA1 promoter
reporter, as well as empty vector (EV) or wild-type GR (GRwt) expression vector. Cells were treated 24 hours after transfection with either B. ethanol
vehicle (−HC) or C. 1 μg/mL HC (+HC) in serum-free medium and assayed for luciferase activity following a 48 hour incubation. Bars represent the
mean of technical replicates, and error bars represent standard deviation (N = 3). For B., statistically significant changes in Ch25h promoter activity
relative to the EV control for each reporter are indicated: one asterisk, p < 0.05 (significant); two asterisks, p < 0.005 (very significant); three asterisks,
p < 0.0005 (very highly significant). For C., statistically significant changes in Ch25h promoter activity in response to EV and GRwt transfections are
indicated relative to the EV transfection for each reporter from the corresponding -HC experiment in B.
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http://www.biomedcentral.com/1471-2407/14/275expression, and in the presence of HC, the activity of the
gene decreases due to the dissociation of GR from the
promoter.
Discussion
We have previously shown that unliganded GR is a posi-
tive regulator of BRCA1 expression, and that the pres-
ence of ligand negates this regulation. Here, we have
continued to explore the role of unliganded GR in the
breast, and report the first identification of potential tar-
gets of unliganded GR. Expression microarray analysis
revealed 343 genes that were positively regulated by
unliganded GR, thus illuminating a previously unknown
role for unliganded GR in the regulation of a network of
genes and adding a new dimension to the GR signaling
pathway. We selected five targets of positive regulation
by unliganded GR for validation and further analysis.Both Ch25h and Hsd11b1 were repressed by the addition
of HC, and Ch25h appeared to be regulated by unli-
ganded GR through a similar mechanism as that re-
ported for Brca1. Oas2 and Slc5a9 appeared to be
activated by both unliganded and liganded GR and may
represent a different class of unliganded GR targets.
In the current study, the expression patterns of Ch25h
indicate that it is regulated similarly to Brca1 in both the
presence and absence of HC. The Ch25h enzyme is respon-
sible for converting cholesterol into 25-hydroxycholesterol,
which has been shown to inhibit cell growth and induce
apoptosis [35]. The Ch25h gene is present in the majority
of vertebrate species, being expressed at low levels in brain,
lung, heart, and kidney tissues, but is absent from lower or-
ganisms such as yeast and flies [36]. While Ch25h gene ex-
pression is low in resting immune cells, it is induced
several hundred-fold when cells are activated with various






















































































































































































































































Figure 10 GR activates the Ch25h promoter region between −375 and −225 bp only in the absence of HC in EPH-4 clone cell lines
EV-50 and shGR-19. EPH-4 clone cell lines A-B. EV-50 and C-D. shGR-19 were transiently transfected with the Ch25h promoter reporters Ch25h-9-pRL,
Ch25h-10-pRL, Ch25h-11-pRL Ch25h-11.5-pRL Ch25h-12-pRL, and the L6-pRL BRCA1 promoter reporter, as well as empty vector (EV) or wild-type GR (GRwt)
expression vector. Cells were treated 24 hours after transfection with either A and C. ethanol vehicle (−HC) or B and D. 1 μg/mL HC (+HC) in serum-free
medium and assayed for luciferase activity following a 48 hour incubation. Bars represent the mean of technical replicates, and error bars represent
standard deviation (N = 3). For A and C., data was normalized to the EV control in the Ch25h-9-pRL transfection (ie. separately for each cell line). Statistically
significant changes in Ch25h promoter activity relative to the EV control for each reporter are indicated: one asterisk, p < 0.05 (significant); two asterisks,
p < 0.005 (very significant); three asterisks, p < 0.0005 (very highly significant). For B and D., data was normalized to the EV control in the Ch25h-9-pRL
transfection from the corresponding -HC experiments in A and C. Statistically significant changes in Ch25h promoter activity in response to EV and GRwt
transfections are indicated relative to the EV transfection for each reporter from the corresponding -HC experiments in A and C.
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enzyme in immune system regulation [28,29]. According to
IPA analysis, Ch25h appeared in the top network signaling
hub regulated by unliganded GR that was centered on im-
mune system and inflammatory signaling. In this network,
Ch25h shared indirect interactions with various factors
known to be involved in pro-apoptotic pathways, such as
Dnase2a [37], as well as several members of the Irf and Oas
families, which were also found by our microarray as tar-
gets of unliganded GR.
In support of our previously reported model of unli-
ganded GR as a positive regulator of gene expression, we
found that GR physically interacted with a specific re-
gion (between −477 to −219 bp) of the Ch25h promoter
in the absence of ligand, while the addition of HC abol-
ished this interaction. Furthermore, the activity of vari-
ous Ch25h reporters containing the region between−375 and −225 bp increased following the addition of
exogenous GR in the absence of ligand, while GR
addition had no effect on a Ch25h reporter that lacked
this region. Analysis of predicted transcription factor
binding sites by Alibaba2.1 (http://www.gene-regulation.
com) did not reveal any GRE sites within this sequence.
Collectively, these results suggest that Ch25h is regu-
lated by unliganded GR through a similar molecular
mechanism as we have described for BRCA1 [13].
The Hsd11b1 gene encodes the enzyme Hsd11b1,
which is responsible for controlling the biological activ-
ity of glucocorticoids in target tissues. Hsd11b1 is exten-
sively expressed, particularly in metabolic tissues such as
liver, muscle, and adipose [38]. This enzyme is involved
in mechanisms of both innate and acquired immune sys-
tem modulation, with its expression being enhanced in
response to a variety of cytokines and inflammatory

































































































Figure 11 GRΔLBD activates the Ch25h promoter in the presence and absence of HC. EPH-4 cells were transiently transfected with the
Ch25h promoter reporters A. Ch25h-11.5-pRL and B. Ch25h-12-pRL as well as with expression vectors for GABPα/β (GABP), full-length GR (GR FL)
and GR lacking the ligand binding domain (GRΔLBD). Cells were treated 24 hours after transfection with either ethanol vehicle (−HC) or 1 μg/mL
HC (+HC) and assayed for luciferase activity following a 48 hour incubation. Bars represent the mean of technical replicates, and error bars represent
standard deviation (N = 3). Statistically significant changes in Ch25h promoter activity relative to the EV (−HC) transfection are indicated: one asterisk,
p < 0.05 (significant); two asterisks, p < 0.005 (very significant).
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http://www.biomedcentral.com/1471-2407/14/275stimuli [39,40]. Accordingly, IPA analysis revealed that
Hsd11b1 was associated with a network involving several
of the same factors as those appearing in the signaling
hub with Ch25h, including Dnase2a and several mem-
bers of the Irf and Oas gene families (data not shown).
However, this second network was associated with a
slightly lower IPA network score, implying more extrap-
olated connections between our gene set and the identi-
fied network. Similar to Brca1 and Ch25h, Hsd11b1
expression was negatively regulated by HC. However,
Hsd11b1 expression was not repressed by treatment with
RU-486, and our ChIP experiments did not show evi-
dence of GR binding to either the distal P1 or proximal
P2 promoters of the Hsd11b1 gene in the absence (or
presence) of ligand (data not shown), which may indi-
cate that this gene is either regulated by unliganded GR
through an alternate indirect mechanism, or that this
interaction occurs outside the region defined by our
ChIP primers.
Expression of both Oas2 and Slc5a9 was decreased
when GR was depleted but in contrast to Ch25h and
Hsd11b1, these genes were significantly activated by HC
addition. We suggest that in the absence of hormone,
these genes are bound by unliganded GR, where it con-
tributes to the positive regulation of these genes as ob-
served in our microarray analysis. During HC treatment,
GR remains bound to the promoter, perhaps via a different
protein complex or through a canonical GRE. This offers
an explanation for the HC-responsiveness of both Oas2
and Slc5a9, which each display kinetics characteristic of a
canonical GRE in response to glucocorticoid binding, such
as the IκB-α gene, which is induced 23-fold in response to
dexamethasone [41]. Promoter analysis using Alibaba2.1revealed that both Oas2 and Slc5a9 contain one or more
GRE consensus sequences within their promoter regions.
While the binding of unliganded GR to a canonical GRE
has not been reported thus far, ChIP-seq analysis of GR
binding in A549 lung cells has previously revealed ap-
proximately 2600 genes that are weakly bound by unli-
ganded GR [17], representing a mechanism through
which GR upregulates genes both in the absence and pres-
ence of hormone. This theory merits further investigation.
Beyond our candidate gene analysis, GOEAST and IPA
functional analyses revealed that a number of genes
positively regulated by unliganded GR were involved in
pro-apoptotic pathways, including Dnase2a, Casp1,
Casp4, Card11, Xaf1, Hsh2d, and multiple members of
the Irf and Tnf family of genes. In contrast, the genes
negatively regulated by unliganded GR appeared to be
involved in various developmental and morphogenetic
processes, and several of these were involved in anti-
apoptotic processes, such as Faim3, Bcl7c, Bcl2l11,
Smad6, Atf5, and Adora1. Among the targets of positive
regulation by unliganded GR included several Interferon
Regulatory Factors (Irfs) and members of the 2′,
5’-oligoadenylate synthetase (Oas) gene family, which
are collectively induced in response to interferons (IFNs)
[42-44]. IFN-inducible genes are often associated with
apoptotic pathways, and some of these factors have been
reported to be regulated by BRCA1 [45], which is known
to participate in the maintenance of genomic integrity
through mediation of both DNA repair and apoptosis
mechanisms in the breast [46,47]. A number of other
BRCA1-related factors known to participate in DNA re-
pair and apoptotic events, such as Brca2 [48], Fancd2 [49],
and Recql [50], were positively regulated by unliganded
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genes upregulated by unliganded GR. BRCA1 has recently
been found to upregulate the activity of phosphorylated
GR, and this activation was required for GR autoregula-
tion [51]. It is possible that a cooperative feedback loop
exists between BRCA1 and GR, whereby levels of BRCA1
predict levels of GR, and vice versa, and this may repre-
sent a mechanism of regulating basal levels of unliganded
GR within the breast.
It is well established that glucocorticoids and liganded
GR are required for the growth and maintenance of the
mammary gland, as well as the suppression of apoptosis
during functional differentiation [52]. However, during
quiescence and involution, glucocorticoid levels are at a
minimum, which suggests a role for unliganded GR in
these processes [52,53] (Figure 12). Maintenance of the
quiescent adult breast is not dependent upon glucocorti-
coids, and, as a result, experiences limited proliferation
and differentiation [53]. During this period, targets of
unliganded GR are upregulated, and the higher level of
pro-apoptotic factors produced could be responsible for
helping to clear abnormal cells. Levels of intracellular
glucocorticoids, particularly cortisol, rise gradually during
pregnancy [54-57], where the breast experiences extensive
proliferation of the terminal ductal lobuloalveolar units
(TDLUs) [58]. At parturition, cortisol levels rise dramatic-
ally [54,57], and the breast undergoes functional differenti-
ation of the TDLUs, marking the initiation of lactation
[59]. Liganded GR is known to support acinus formation
and spatial organization during pregnancy and lactation











Figure 12 Summary of signaling networks and pathways regulated b
GR appear to possess opposing functions in the breast. While liganded GR
during lactation, several unliganded GR targets appear to be pro-apoptotic
targets of liganded GR signaling. Factors in purple represent targets reveale
Targets in bold purple represent candidates investigated during our microamaintenance of tight junctional complexes, such as adhe-
rens junctions proteins ZO-1 and β-catenin [12,60,61].
Liganded GR also upregulates signal transducer and acti-
vator of transcription 5 (STAT5) and enhances β-casein
gene transcription during lactation [62-64]. Signaling by
liganded GR in this manner maintains a state of terminal
differentiation in the breast, both by upregulating the ex-
pression of the above-mentioned genes involved in breast
morphogenesis, and negating signaling by unliganded GR,
thus preventing apoptosis and the onset of involution. De-
creased Brca1 expression reported during lactation in the
mouse mammary gland may be reflective of this loss of
unliganded GR activation [53]. The cessation of suckling
initiates a decrease in circulating cortisol levels, which in-
duces post-lactational regression (involution), an apoptotic
process whereby the breast reverts to a quiescent, pre-
pregnancy state [3,65]. During involution, signaling by
liganded GR is lost, and signaling by unliganded GR would
be re-established, thus upregulating pro-apoptotic factors
to encourage involution, and repressing factors involved in
differentiation. Accordingly, the decrease in cortisol asso-
ciated with induction of involution coincides with an in-
crease in Brca1 expression in mice [53].
While ligand-independent activity has been previously
reported for other nuclear receptors, including GR, this
activity has been in response to other stimuli [14,66-69].
In contrast, our previous and current work indicates that
unliganded GR constitutively regulates basal expression
of its target genes, which suggests that the endogenous
levels of unliganded GR itself may directly determine the












y the glucocorticoid receptor. Targets of liganded and unliganded
is involved in maintaining functional differentiation, such as occurs
, and may be involved in involution. Factors in blue represent known
d by our microarray to be positively regulated by unliganded GR.
rray validation.
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http://www.biomedcentral.com/1471-2407/14/275where maintenance of this state is not dependent upon
glucocorticoids, the greater availability of unliganded GR
is postulated to increase pro-apoptotic signaling, which
could result in the elimination of abnormal cells. Unli-
ganded GR thus offers protection from tumourigenesis
during this period, via upregulation of pro-apoptotic fac-
tors and potentially through upregulation of Hsd11b1,
which may protect the breast from low levels of gluco-
corticoids through their inactivation [70]. We suggest
that during periods of stress, levels of unliganded GR are
lowered due to a shift towards liganded GR signaling,
and it is thus less able to fulfill its protective, pro-
apoptotic role. According to this model, downregulation
or loss of constitutive activity of unliganded GR would
be selected for during cellular transformation since this
would confer cells with the ability to resist apoptosis. As
reported previously, long-term epigenetic regulation of
GR (specifically promoter methylation) represents a
mechanism through which an individual’s susceptibility
to stress may be altered [71]. Furthermore, low expres-
sion of GR has been associated with poorer outcome in
estrogen receptor (ER) positive breast cancers [72], and
the GR gene NR3C1 has been reported to be mutated in
triple-negative breast cancers, indicating that inactivation of
GR is part of the transformation process in these tumours
[73]. A reduction in GR levels as a consequence of pro-
moter methylation or mutation would subsequently result
in decreased signaling to pro-apoptotic targets due to the
loss of positive regulation by unliganded GR, thus potenti-
ating the risk of transformation through the accumulation
of abnormal cells. This is consistent with the observed de-
crease in GR levels in pathologically advanced breast
tumours [74]. Thus, we suggest that the activity of unli-
ganded GR in the breast is primarily anti-tumourigenic,
and we propose that stress promotes malignant transform-
ation in breast cells since binding of cortisol abolishes the
activities of unliganded GR, the result being similar to
mutation-induced loss of GR gene expression.
Conclusion
In conclusion, this study offers additional insight into the
role of unliganded GR in the breast, and specifically af-
fords us knowledge of a previously uncharacterized net-
work of transcriptional regulation by unliganded GR.
While glucocorticoids and liganded GR appear to suppress
apoptosis and facilitate differentiation in the breast, a large
proportion of targets of positive regulation by unliganded
GR appear to be involved in pro-apoptotic pathways. We
suggest that signaling through unliganded GR may repre-
sent a mechanism of suppressing the risk of tumourigen-
esis in the breast by encouraging apoptosis of abnormal
cells. Additional study is warranted to further elucidate
the role of unliganded GR levels in modulating breast
cancer risk.Additional files
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